Androgen receptor in breast cancer: The “5W” questions

Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle specifically AR-positive BC patients. The prognostic and predictive role of AR in BC is a matter of debate, since the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravaioli, Sara, Maltoni, Roberta, Pasculli, Barbara, Parrella, Paola, Giudetti, Anna Maria, Vergara, Daniele, Tumedei, Maria Maddalena, Pirini, Francesca, Bravaccini, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468319/
https://www.ncbi.nlm.nih.gov/pubmed/36111296
http://dx.doi.org/10.3389/fendo.2022.977331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468319/
https://www.ncbi.nlm.nih.gov/pubmed/36111296
http://dx.doi.org/10.3389/fendo.2022.977331

Ejemplares similares